scholarly journals Clinical Outcomes and Prognostic Factors of Salvage Treatment for Local Lymph Node Recurrence After Radical Resection of Oesophageal Carcinoma

2021 ◽  
Vol Volume 13 ◽  
pp. 5845-5853
Author(s):  
Liang Gu ◽  
Yangchen Liu ◽  
Hongxue Ye ◽  
Fei Gao ◽  
Xiaoxiang Yin ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Lymph Node ◽  
Clinical Outcomes ◽  
Radical Resection ◽  
Oesophageal Carcinoma ◽  
Salvage Treatment ◽  
Lymph Node Recurrence ◽  
Local Lymph Node

scholarly journals Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Jie Chen ◽  
Wenming Yin ◽  
Hui Yao ◽  
Wendong Gu
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Lymph Node ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Regional Lymph Node ◽  
Radical Resection ◽  
Salvage Treatment ◽  
Lymph Node Recurrence

Abstract Background Patients with regional lymph node recurrence after radical resection of esophageal cancer have poor therapeutic outcomes. Currently, there is no standard treatment for regional lymph node recurrence, and its prognostic risk factors are not well-understood. This study retrospectively analyzed 83 patients with postoperative regional lymph node recurrence after radical resection of esophageal squamous cell carcinoma. The aim was to evaluate the clinical efficacy and prognostic factors of salvage radiotherapy with or without chemotherapy in these patients. Methods The survival and prognostic factors of 83 patients with esophageal squamous cell carcinoma with regional lymph node recurrence after radical surgery were retrospectively analyzed. All patients underwent radiotherapy, of which 74 patients received volumetric modulated arc therapy (VMAT), 9 patients received three-dimensional conformal radiation therapy (3DCRT), administered using a conventional segmentation protocol with a dose distribution range of 50.4–66.2Gy (median dose of 60Gy). In total, 41 patients received radiotherapy alone, 42 received radiotherapy combined with chemotherapy, and the concurrent chemotherapy regimen was mainly composed of either platinum or fluorouracil monotherapy, except for 4 patients who were given 5-fluorouracil plus platinum (FP) or paclitaxel plus platinum (TP). Results The median follow-up time was 24 (range, 9–75) months. The overall survival (OS) rates at 1 year, 2 years, 3 years, and 5 years were 83.0, 57.1, 40.1, and 35.1%, respectively. The median overall survival (OS) time was 18 (range, 5–75) months. The 3-year survival rate was 47.5% in patients with radiation alone and 41.9% in patients receiving concurrent chemoradiotherapy(p = 0.570), while the response rate (CR + PR) in those two groups was 73.2 and 91.4%, respectively. By multivariate analysis of OS, age (worse in younger patients, p = 0.034) was found to be significantly associated with disease prognosis. The commonly toxicities were esophagitis, neutropenia and anemia. 18% patients experienced grade 3 toxicity and no treatment-related death occurred. Conclusions These results of this retrospective analysis suggest that radiotherapy with or without chemotherapy is an effective and feasible salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.

scholarly journals Prognostic factors for T1-2 colorectal cancer after radical resection: Lymph node distribution is a valuable predictor of its survival

2021 ◽  
Vol 44 (1) ◽  
pp. 241-246
Author(s):  
Xing Huang ◽  
Hao Liu ◽  
Xiangqi Liao ◽  
Zhigang Xiao ◽  
Zhongcheng Huang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Radical Resection ◽  
Node Distribution ◽  
Valuable Predictor

scholarly journals Clinical Outcomes of Isolated Regional Lymph Node Recurrence in Patients With Malignant Cutaneous Melanoma

2019 ◽  
Vol 39 (6) ◽  
pp. 3147-3157
Author(s):  
JEANNY KWON ◽  
YOUNG A. KIM ◽  
CHEOL LEE ◽  
BYOUNG HYUCK KIM ◽  
SUZY KIM ◽  
...  
Keyword(s):  
Lymph Node ◽  
Clinical Outcomes ◽  
Cutaneous Melanoma ◽  
Regional Lymph Node ◽  
Lymph Node Recurrence ◽  
Malignant Cutaneous Melanoma

Identification of prognostic factors in patients with cervical cancer and supraclavicular lymph node recurrence

2011 ◽  
Vol 123 (2) ◽  
pp. 253-256 ◽  
Author(s):  
Kung-Chu Ho ◽  
Chun-Chieh Wang ◽  
Jian-Tai Qiu ◽  
Chyong-Huey Lai ◽  
Ji-Hong Hong ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Supraclavicular Lymph Node ◽  
Lymph Node Recurrence

scholarly journals OC-0591: Anatomical and functional pattern of local-lymph node recurrence after prostatectomy based on multiparametric MR

2015 ◽  
Vol 115 ◽  
pp. S288
Author(s):  
G. Sancho Pardo ◽  
D. Hernandez ◽  
D. Salas ◽  
D. Giménez ◽  
P. Buitrago ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Recurrence ◽  
Local Lymph Node

scholarly journals Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy

PLoS ONE ◽  
2021 ◽  
Vol 16 (9) ◽  
pp. e0256778
Author(s):  
Dowook Kim ◽  
Dong-Yun Kim ◽  
Jae-Sung Kim ◽  
Sung Kyu Hong ◽  
Seok-Soo Byun ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Salvage Treatment ◽  
Node Positive ◽  
Psa Nadir ◽  
Lymph Node Positive

Introduction The optimal salvage treatment strategies for lymph node-positive (LNP) patients after radical surgery have not been clearly defined in prostate cancer with biochemical recurrence or persistence of elevated prostate-specific antigen (PSA). In this study, we compared the clinical outcomes of two different salvage treatments, androgen deprivation therapy (ADT) alone versus ADT with radiotherapy (RT). We also investigated prognostic factors that could support the use of ADT with RT in LNP prostate cancer. Materials and methods We retrospectively reviewed 94 LNP prostate cancer patients who underwent radical prostatectomy (RP) followed by salvage treatment between 2004 and 2018. Salvage treatments involved either ADT alone or ADT with RT according to the clinical judgment of the physician. We analyzed clinicopathological and treatment factors related to 2nd biochemical failure (2nd BCF), clinical progression (CP), and progression-free survival (PFS). The cumulative failure after salvage treatment was defined as including both 2nd BCF and CP. Results The median duration of follow-up was 55 months (interquartile range, 35–97 months). Thirty-seven (39.4%) patients were treated with ADT alone, and 57 patients (60.6%) were treated with a combination of ADT with RT. During follow-up period, the incidence of failure after salvage treatment in the ADT alone group and the combined treatment group was 89.2% and 45.6%, respectively (HR, 22.4; 95% CI 5.43–92.1; P < 0.001). The combination of ADT with RT was associated with better 2nd BCF and PFS than ADT alone (P = 0.007 and P = 0.015, respectively). In multivariate analyses, number of positive LN ≥ 2 and PSA nadir ≥ 0.005 ng/ml after RP were associated with poor 2nd BCF, CP, and PFS after salvage treatment. Salvage by combined ADT plus RT showed better 2nd BCF and PFS than ADT alone. Specifically, patients with number of positive LN ≥ 2 or PSA nadir ≥ 0.005 ng/ml after RP showed better 2nd BCF (P = 0.004) or PFS (P = 0.011) when treated with ADT plus RT rather than ADT alone. Conclusions In patients with LNP prostate cancer, salvage ADT plus RT improved 2nd BCF and PFS compared to ADT alone. In particular, when the patients had more than two positive lymph nodes or PSA nadir ≥ 0.005 ng/ml after RP, ADT with RT seems to be a more beneficial salvage treatment resulting in better 2nd BCF and PFS.

Sign in / Sign up

Export Citation Format

Share Document